We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel AI-Powered Method for Tissue Analysis Improves Understanding of Disease Pathology

By LabMedica International staff writers
Posted on 11 Jun 2024
Print article
Image: The new AI-powered statistics method has the potential to improve tissue and disease research (Photo courtesy of 123RF)
Image: The new AI-powered statistics method has the potential to improve tissue and disease research (Photo courtesy of 123RF)

Scientists at Brown University (Providence, RI, USA) and the University of Michigan (Ann Arbor, MI, USA) have created a groundbreaking computational technique to examine complex tissue data, potentially revolutionizing our understanding of diseases and their treatment. The method, known as Integrative and Reference-Informed tissue Segmentation (IRIS), utilizes machine learning and artificial intelligence to provide biomedical researchers with accurate insights into tissue development, disease pathology, and tumor structuring. IRIS employs spatially resolved transcriptomics (SRT) data and incorporates single-cell RNA sequencing data as a reference. This approach allows for the simultaneous examination of multiple tissue layers and accurately identifies different regions with exceptional computational speed and precision. In contrast to traditional methods that offer averaged data from tissue samples, SRT delivers a much more detailed perspective, locating thousands of specific points within a single tissue section.

Handling vast and complex datasets has always posed significant challenges, and IRIS addresses these by using algorithms to sift through data, segmenting various functional domains, such as tumor areas, and shedding light on cellular interactions and the dynamics of disease progression. Unlike existing methods, IRIS directly maps the cellular composition of tissues and delineates biologically meaningful spatial domains, enhancing the comprehension of cellular activities that drive tissue functions. The developers of IRIS tested it on six SRT datasets, assessing its effectiveness compared to other spatial domain analysis methods. As SRT technologies gain traction and become more widely used, the creators of IRIS anticipate that it will contribute to identifying new clinical intervention points or pharmaceutical targets, thereby enhancing personalized treatment strategies and ultimately improving patient health outcomes.

"The computational approach of IRIS pioneers a novel avenue for biologists to delve into the intricate architecture of complex tissues, offering unparalleled opportunities to explore the dynamic processes shaping tissue structure during development and disease progression," said Xiang Zhou, professor of biostatistics at the University of Michigan School of Public Health. "Through characterizing refined tissue structures and elucidating their alterations during disease states, IRIS holds the potential to unveil mechanistic insights crucial for understanding and combating various diseases." The researchers' findings were published in the journal Nature Methods on June 6, 2024.

Related Links:
Brown University
University of Michigan

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.